$KIDS

Pritzker Jennifer N. sold $525K of KIDS (indirect holdings)

Pritzker Jennifer N. sold 22,500 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at $23.35 ($0.53M total) on 2026-09-02.

Original reporting
SEC EDGAR · Pritzker Jennifer N.
Published Sep 4, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KIDS
Neutral
medium confidence
Mentioned
$KIDS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSNeutralLow
01

Why it matters

The disclosed sale is the first public report of this insider transaction, providing new data for traders.

02

Market read

New insider sale adds modest negative sentiment but limited trading impact.

03

What to watch

Potential upcoming regulatory or product developments not disclosed.

Relevance 5/10Novelty 4/10Timing: today

Background

SEC Form 4 filing reports insider transaction for Orthopedics Corp (KIDS).

Company-level read

Ticker impact

$KIDSNeutralMedium confidence
Context

Form 4 disclosed Jennifer N. Pritzker sold 22,500 shares of Orthopedics Corp for $525,375.

Expected impact

Potential slight downward pressure, likely limited.

Evidence & confidence

Sale represents ~0.35% of post‑transaction holdings; market may view as routine.

Market effects

Minimal impact on orthopedics sector; insider activity is routine.

None

None

Counterpoint

Sale could be a pre‑emptive move before negative news, suggesting caution.

Key entities

  • Jennifer N. Pritzker

    10% owner of Orthopedics Corp.

  • Orthopedics Corp

    Ticker KIDS, medical device manufacturer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Crosses $70M as Guidance Climbs Higher

OrthoPediatrics (KIDS) reported Q2 revenue of $70.5M, up 15% YoY, and raised 2026 guidance to $265M-$269M. Trauma and Deformity revenue grew 26%, while international sales rose 22%. Despite higher expenses, gross margin expanded to 74% and adjusted EBITDA doubled to $6.8M. Net loss remained at $7.2M, and cash reserves declined to $47.9M.

$KIDSMed

OrthoPediatrics Corp. Q2 2026 Earnings Call Summary

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.